DOT1 L INHIBITORS FOR USE IN THE TREATMENT OF LEUKEMIA
    2.
    发明公开
    DOT1 L INHIBITORS FOR USE IN THE TREATMENT OF LEUKEMIA 审中-公开
    DOT1-L-INHIBITOREN ZUR VERWENDUNG BEI DER BEHANDLUNG VONLEUKÄMIE

    公开(公告)号:EP2934550A1

    公开(公告)日:2015-10-28

    申请号:EP13821345.9

    申请日:2013-12-20

    申请人: Epizyme, Inc.

    IPC分类号: A61K31/7076 A61P35/00

    摘要: The present invention relates to DOT1L inhibitors. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.

    摘要翻译: 本发明涉及DOT1L抑制剂。 本发明还涉及含有这些化合物的药物组合物和通过将这些化合物和药物组合物施用于有需要的受试者来治疗其中DOT1介导的蛋白质甲基化成为其中一部分的疾病的方法。

    INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF
    4.
    发明公开
    INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF 审中-公开
    抑制剂蛋白质转运蛋白DOT1L UND VERWENDUNGSVERFAHRENDAFÜR

    公开(公告)号:EP2882750A1

    公开(公告)日:2015-06-17

    申请号:EP13827414.7

    申请日:2013-08-12

    申请人: Epizyme, Inc.

    摘要: The present invention relates to DOT1L inhibitors and methods of identifying, designing, or optimizing them. The present invention also relates to crystals of DOT1L-inhibitor complexes, the crystal structures thereof, and the use of the crystal structures. Also disclosed are pharmaceutical compositions containing these DOT1L inhibitors and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.

    摘要翻译: 本发明涉及DOT1L抑制剂及其鉴定,设计或优化方法。 本发明还涉及DOT1L抑制剂复合物的晶体,其晶体结构以及晶体结构的用途。 还公开了含有这些DOT1L抑制剂的药物组合物和通过将这些化合物和药物组合物施用于有需要的受试者来治疗其中DOT1介导的蛋白质甲基化部分如癌症和神经障碍的疾病的方法。